Overview

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Status:
NOT_YET_RECRUITING

Trial end date:
2030-12-01

Target enrollment:

Participant gender:

Summary

This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.

Phase:

PHASE1

Details

Lead Sponsor:

Bionoxx Inc.

Treatments:

atezolizumab
Hydroxyurea